Combined Treatment of RFA and Sorafenib on Recurrent HCC (REPEAT)

Army Medical University

Status: Unknown

Conditions: Sorafenib; Radiofrequency Ablation; HCC

Treatments: Other: RFA + Sorafenib; Other: RFA

Study type: Interventional

Funder types: Other

Identifiers

NCT01470495

swhb005

Details and patient eligibility

About

RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.

Enrollment: 430 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• recurrent HCC after curative resection
• without gender restriction
• age between 18 to 75 years
• The liver function showed no worse than Child-Pugh B
• tumor nodes were less than 5cm and no more than 3 nodules

Exclusion criteria

• Pregnancy patients
• With extrahepatic tumor or lymphnode metastasis
• Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

430 participants in 2 patient groups

RFA+Sorafenib

Experimental group

Description:

to treat recurrent HCC both with RFA and Sorafenib

Treatment:

Other: RFA + Sorafenib

RFA group

Active Comparator group

Description:

To treat recurrent HCC with RFA

Treatment:

Other: RFA